Shopping Cart
Remove All
Your shopping cart is currently empty
AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells. [2]

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $139 | In Stock | In Stock | |
| 5 mg | $347 | In Stock | In Stock | |
| 10 mg | $538 | In Stock | In Stock | |
| 25 mg | $868 | In Stock | In Stock | |
| 50 mg | $1,180 | In Stock | In Stock | |
| 100 mg | $1,590 | In Stock | In Stock |
| Description | AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells. [2] |
| In vitro | METHODS: PCa cells (LNCaP, VCaP, 22RV1, and LAPC4) were treated with different concentrations of AU-15330 (0.1, 1 μM). RESULTS AU-15330 attenuated the growth of these cells and induced apoptotic cell death, while having no antiproliferative effect on benign or non-neoplastic prostate cells. [1] |
| In vivo | METHODS: AU-15330 (60 mg kg, i.v.) was administered to mice bearing VCaP and C4-2B castration-resistant tumor models, 3 days per week. RESULTS AU-15330 inhibited tumor growth in mice bearing VCaP and C4-2B castration-resistant tumor models without significant toxicity. [1] |
| Molecular Weight | 755.93 |
| Formula | C39H49N9O5S |
| Cas No. | 2380274-50-8 |
| Smiles | C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)CN1CCN(CC1)c1cc(nnc1N)-c1ccccc1O)C(C)(C)C)c1ccc(cc1)-c1scnc1C |
| Storage | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 252.5 mg/mL (334.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.